Patents by Inventor William R. Wolter
William R. Wolter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9308252Abstract: Disclosed are vaccines and vaccine adjuvants useful in the treatment and/or prevention of infection and diseases associated with infectious pathogens, such as tetanus, as well as diseases associated with biological toxins. Also provided are methods of preparing an adjuvant and the vaccine containing the adjuvant. Methods are also provided for vaccinating/immunizing an animal against infection and diseases associated with infectious pathogens, such as tetanus, and other diseases associated with biological toxins. Adjuvant materials are presented that are prepared from an extracellular matrix material. The adjuvants are demonstrated to enhance the immunogencity of an infectious pathogen antigen or biological toxin antigen of interest, as well as to enhance the survival of an immunized animal.Type: GrantFiled: January 30, 2007Date of Patent: April 12, 2016Assignees: COOK BIOTECH, INC., UNIVERSITY OF NOTRE DAMEInventors: Mark A. Suckow, William R. Wolter, Paul Hall
-
Patent number: 9283266Abstract: Disclosed are compositions and pharmaceutical preparations suitable for inhibiting metastasis of a malignant cancer in an animal. Methods for inhibiting and/or eliminating metastasis in an animal are also provided. In some embodiments, the preparations and compositions comprise a whole cell tumor preparation comprising tumor tissue cells and tumor connective tissue stroma. The disclosure also provides methods for preparing the preparations and pharmaceutical preparations. Inhibition of metastasis of malignant prostate cancer to the lung is shown in vivo.Type: GrantFiled: February 28, 2008Date of Patent: March 15, 2016Assignee: UNIVERSITY OF NOTRE DAMEInventors: Mark A. Suckow, William R. Wolter, Valerie Sailes
-
Patent number: 9220770Abstract: Disclosed are vaccines and vaccine adjuvants useful in the treatment and/or prevention of infection and diseases associated with infectious pathogens, such as tetanus, as well as diseases associated with biological toxins. Also provided are methods of preparing an adjuvant and the vaccine containing the adjuvant. Methods are also provided for vaccinating/immunizing an animal against infection and diseases associated with infectious pathogens, such as tetanus, and other diseases associated with biological toxins. Adjuvant materials are presented that are prepared from an extracellular matrix material. The adjuvant may also be described as a heterologous acellular collagenous tissue preparation. The adjuvants are demonstrated to enhance the immunogencity of an infectious pathogen antigen or biological toxin antigen of interest, as well as to enhance the survival of an immunized animal.Type: GrantFiled: August 26, 2010Date of Patent: December 29, 2015Assignees: The University of Notre Dame, Cook Biotech, Inc.Inventors: Mark A. Suckow, William R. Wolter, Paul J. Hall
-
Patent number: 8802113Abstract: Compositions suitable for use as adjuvants in the preparation of vaccines, particularly those vaccines useful in the treatment of cancer, are provided. Methods for inhibiting tumor growth in an animal are also disclosed. Methods for immunizing an animal against cancer, such as prostate cancer, are also described. The adjuvants described are comprised of an extracellular matrix material, such as small intestinal submucosal (SIS) tissue. The preparations may take the form of sheets, gels, liquids (injectable), trocar, or other solid or semi-solid preparation. The invention provides for enhanced tumor inhibition of 2-fold or greater, compared to vaccine preparations without the extracellular matrix material, or from 4- to 5-fold, compared to preparations without the adjuvant promoting extracellular materials.Type: GrantFiled: October 19, 2007Date of Patent: August 12, 2014Assignee: University of Notre DameInventors: William R. Wolter, Mark S. Suckow
-
Patent number: 8778360Abstract: Compositions suitable for use as adjuvants in the preparation of vaccines, particularly those vaccines useful in the treatment of cancer, are provided. Methods for inhibiting tumor growth in an animal are also disclosed. Methods for immunizing an animal against cancer, such as prostate cancer, are also described. The adjuvants described are comprised of an extracellular matrix material, such as small intestinal submucosal (SIS) tissue. The preparations may take the form of sheets, gels, liquids (injectable), trocar, or other solid or semi-solid preparation. The invention provides for enhanced tumor inhibition of 2-fold or greater, compared to vaccine preparations without the extracellular matrix material, or from 4- to 5-fold, compared to preparations without the adjuvant promoting extracellular materials.Type: GrantFiled: October 20, 2006Date of Patent: July 15, 2014Assignee: University of Notre DameInventors: Mark A. Suckow, William R. Wolter
-
Patent number: 8257715Abstract: Compositions comprising a tissue vaccine that include a mixture of heterogeneous tissue obtained from tumors and connective tissues. Vaccines comprising these compositions are also provided, as well as methods of using the vaccines in the treatment and/or inhibition of tumor growth, and particularly prostate tumor growth and cancers. The preparations may be defined as vaccines comprising tumor cells and connective (stromal) tissues derived from xenogeneic animals. Preparations comprising the tissue vaccines are provided using tissue harvested directly from tumors. Methods for preventing de novo development of cancer are also disclosed. A tissue vaccine comprising glutaraldehyde-(GFT) treated tissue prepared from tumor and connective tissue reduces the incidence of autochthonous prostate cancer. A tissue vaccine comprising a potassium thiocyanate extract (PTE) preparation of a tumor and connective tissue is also provided.Type: GrantFiled: August 24, 2005Date of Patent: September 4, 2012Assignee: University of Notre DameInventors: Mark A. Suckow, William R. Wolter, Morris Pollard
-
Patent number: 8062646Abstract: Compositions comprising a tissue vaccine that include a mixture of heterogeneous tissue obtained from tumors and connective tissues. Vaccines comprising these compositions are also provided, as well as methods of using the vaccines in the treatment and/or inhibition of tumor growth, and particularly prostate tumor growth and cancers. The preparations may be defined as vaccines comprising tumor cells and connective (stromal) tissues derived from xenogeneic animals. Preparations comprising the tissue vaccines are provided using tissue harvested directly from tumors. Methods for preventing de novo development of cancer are also disclosed. A tissue vaccine comprising glutaraldehyde-(GFT) treated tissue prepared from tumor and connective tissue reduces the incidence of autochthonous prostate cancer. A tissue vaccine comprising a potassium thiocyanate extract (PTE) preparation of a tumor and connective tissue is also provided.Type: GrantFiled: October 25, 2007Date of Patent: November 22, 2011Assignee: University of Notre DameInventors: Mark A. Suckow, William R. Wolter, Morris Pollard
-
Publication number: 20110076305Abstract: Disclosed are vaccines and vaccine adjuvants useful in the treatment and/or prevention of infection and diseases associated with infectious pathogens, such as tetanus, as well as diseases associated with biological toxins. Also provided are methods of preparing an adjuvant and the vaccine containing the adjuvant. Methods are also provided for vaccinating/immunizing an animal against infection and diseases associated with infectious pathogens, such as tetanus, and other diseases associated with biological toxins. Adjuvant materials are presented that are prepared from an extracellular matrix material. The adjuvant may also be described as a heterologous acellular collagenous tissue preparation. The adjuvants are demonstrated to enhance the immunogencity of an infectious pathogen antigen or biological toxin antigen of interest, as well as to enhance the survival of an immunized animal.Type: ApplicationFiled: August 26, 2010Publication date: March 31, 2011Applicants: University of Notre Dame Du Lac, Cook Biotech, Inc.Inventors: Mark A. Suckow, William R. Wolter, Paul J. Hall
-
Publication number: 20100233214Abstract: Compositions suitable for use as adjuvants in the preparation of vaccines, particularly those vaccines useful in the treatment of cancer, are provided. Methods for inhibiting tumor growth in an animal are also disclosed. Methods for immunizing an animal against cancer, such as prostate cancer, are also described. The adjuvants described are comprised of an extracellular matrix material, such as small intestinal submucosal (SIS) tissue. The preparations may take the form of sheets, gels, liquids (injectable), trocar, or other solid or semi-solid preparation. The invention provides for enhanced tumor inhibition of 2-fold or greater, compared to vaccine preparations without the extracellular matrix material, or from 4- to 5-fold, compared to preparations without the adjuvant promoting extracellular materials.Type: ApplicationFiled: October 20, 2006Publication date: September 16, 2010Applicant: University of Notre Dame du LacInventors: Mark A. Suckow, William R. Wolter
-
Publication number: 20100136050Abstract: Disclosed are vaccines and vaccine adjuvants useful in the treatment and/or prevention of infection and diseases associated with infectious pathogens, such as tetanus, as well as diseases associated with biological toxins. Also provided are methods of preparing an adjuvant and the vaccine containing the adjuvant. Methods are also provided for vaccinating/immunizing an animal against infection and diseases associated with infectious pathogens, such as tetanus, and other diseases associated with biological toxins. Adjuvant materials are presented that are prepared from an extracellular matrix material. The adjuvants are demonstrated to enhance the immunogenicity of an infectious pathogen antigen or biological toxin antigen of interest, as well as to enhance the survival of an immunized animal.Type: ApplicationFiled: October 13, 2009Publication date: June 3, 2010Applicants: University of Notre Dame Du Lac, Cook Biotech, Inc.Inventors: Mark A. Suckow, William R. Wolter, Paul J. Hall
-
Publication number: 20090220461Abstract: Disclosed are compositions and pharmaceutical preparations suitable for inhibiting metastasis of a malignant cancer in an animal. Methods for inhibiting and/or eliminating metastasis in an animal are also provided. In some embodiments, the preparations and compositions comprise a whole cell tumor preparation comprising tumor tissue cells and tumor connective tissue stroma. The disclosure also provides methods for preparing the preparations and pharmaceutical preparations. Inhibition of metastasis of malignant prostate cancer to the lung is shown in vivo.Type: ApplicationFiled: February 28, 2008Publication date: September 3, 2009Applicant: University of Notre DameInventors: Mark A. Suckow, William R. Wolter, Valerie Sailes
-
Publication number: 20080260800Abstract: Compositions suitable for use as adjuvants in the preparation of vaccines, particularly those vaccines useful in the treatment of cancer, are provided. Methods for inhibiting tumor growth in an animal are also disclosed. Methods for immunizing an animal against cancer, such as prostate cancer, are also described. The adjuvants described are comprised of an extracellular matrix material, such as small intestinal submucosal (SIS) tissue. The preparations may take the form of sheets, gels, liquids (injectable), trocar, or other solid or semi-solid preparation. The invention provides for enhanced tumor inhibition of 2-fold or greater, compared to vaccine preparations without the extracellular matrix material, or from 4- to 5-fold, compared to preparations without the adjuvant promoting extracellular materials.Type: ApplicationFiled: October 19, 2007Publication date: October 23, 2008Inventors: Mark A. Suckow, William R. Wolter
-
Publication number: 20080160049Abstract: Compositions comprising a tissue vaccine that include a mixture of heterogeneous tissue obtained from tumors and connective tissues. Vaccines comprising these compositions are also provided, as well as methods of using the vaccines in the treatment and/or inhibition of tumor growth, and particularly prostate tumor growth and cancers. The preparations may be defined as vaccines comprising tumor cells and connective (stromal) tissues derived from xenogeneic animals. Preparations comprising the tissue vaccines are provided using tissue harvested directly from tumors. Methods for preventing de novo development of cancer are also disclosed. A tissue vaccine comprising glutaraldehyde-(GFT) treated tissue prepared from tumor and connective tissue reduces the incidence of autochthonous prostate cancer. A tissue vaccine comprising a potassium thiocyanate extract (PTE) preparation of a tumor and connective tissue is also provided.Type: ApplicationFiled: October 25, 2007Publication date: July 3, 2008Applicant: UNIVERSITY OF NOTRE DAME DU LACInventors: Mark A. Suckow, William R. Wolter, Morris Pollard
-
Publication number: 20080107665Abstract: Disclosed are vaccines and vaccine adjuvants useful in the treatment and/or prevention of infection and diseases associated with infectious pathogens, such as tetanus, as well as diseases associated with biological toxins. Also provided are methods of preparing an adjuvant and the vaccine containing the adjuvant. Methods are also provided for vaccinating/immunizing an animal against infection and diseases associated with infectious pathogens, such as tetanus, and other diseases associated with biological toxins. Adjuvant materials are presented that are prepared from an extracellular matrix material. The adjuvants are demonstrated to enhance the immunogencity of an infectious pathogen antigen or biological toxin antigen of interest, as well as to enhance the survival of an immunized animal.Type: ApplicationFiled: January 30, 2007Publication date: May 8, 2008Applicant: University of Notre Dame du LacInventors: Mark A. Suckow, William R. Wolter
-
Patent number: 6951726Abstract: A rapid and sensitive PCR-based assay is provided to facilitate early detection of Edwardsiella ictaluri in channel catfish. This bacteria is the causative agent in the disease, Enteric septicemia of catfish (ESC). Also provided is a method of selecting breeding stock for use in selective breeding programs to improve disease resistance in channel catfish. Also provided is a method of determining the efficacy of vaccines produced against ESC.Type: GrantFiled: September 24, 2002Date of Patent: October 4, 2005Assignees: Mississippi State University, The United States of America as represented by the Department of AgricultureInventors: Anita L. Bilodeau, William R. Wolters, Geoffrey C. Waldbieser, David J. Wise
-
Publication number: 20040058332Abstract: A rapid and sensitive PCR-based assay is provided to facilitate early detection of Edwardsiella ictaluri in channel catfish. This bacteria is the causative agent in the disease, Enteric septicemia of catfish (ESC). Also provided is a method of selecting breeding stock for use in selective breeding programs to improve disease resistance in channel catfish. Also provided is a method of determining the efficacy of vaccines produced against ESC.Type: ApplicationFiled: September 24, 2002Publication date: March 25, 2004Inventors: Anita L. Bilodeau, William R. Wolters, Geoffrey C. Waldbieser, David J. Wise
-
Publication number: 20040055029Abstract: A substantially purebred non-transgenically developed fish produced by selecting fish having at least one desirable trait from a population of same species fish and preparing a DNA fingerprint of the selected fish so as to be able to identify breeder fish by use of selected microsatellite loci identified as being associated with fish having the at least one desired trait, breeding the selected breeder fish to produce offspring having the at least one desired trait. Also provided is a method for producing the substantially purebred non-transgenically developed fish.Type: ApplicationFiled: September 18, 2002Publication date: March 18, 2004Inventors: William R. Wolters, Geoffrey C. Waldbieser, Brian G. Bosworth, Jeffrey T. Silverstein, Edwin H. Robinson
-
Patent number: 4489674Abstract: A method for the induction of 100% triploidy in channel catfish by cold-shocking fertilized eggs at about 5.degree. C. for up to about 1.0 hour starting about 5 minutes after fertilization.Type: GrantFiled: February 25, 1981Date of Patent: December 25, 1984Assignee: Purdue Research FoundationInventors: William R. Wolters, Charles L. Chrisman, George S. Libey